Do you mean the Trimesta combo trial catalyst? Jury is out on that one. Many think + and many believe it will be -. We'll see. Later Pertussis preclinical data update will probably give some support but not likely much - Wall St doesn't care too much about preclinical results. When we finish bridge trial and launch ph1/2 of c-dif enzyme...that's when we go up and stay up, regardless of Trimesta results...which I think will be fine, by the way. But you never can tell.
Market Data 
Markets 
AI
